Abstract
Taxanes antitumour agents such as paclitaxel and docetaxel represent a successful family of chemotherapeutic drugs. Unfortunately, acquired and innate resistance represents a clinical problem for these drugs. We investigated, on a panel of 7 human cancer cell lines, the growth inhibition effect of 3 newly developed taxanes (SB-T-1213, SB-T-1250 and SB-T-101187) with modification at the C10 and C3′ positions of the taxane framework. These positions have been previously characterized as critical to make taxanes highly active against cells overexpressing the efflux pump P-glycoprotein (P-gp). Paclitaxel and docetaxel were used as reference compounds. Results unambiguously indicate the exceptional activity of the novel taxanes toward P-gp positive cells (up to >400 fold higher potency than that of paclitaxel). SB-T-1213 and SB-T-1250 are also substantially more active than the reference compounds against P-gp negative cells. To better understand the mechanisms underlying the enhanced activity of the newly developed taxanes, we performed cell cycle and apoptosis analysis. This study demonstrates that the striking growth inhibition effect exhibited by the novel taxanes is ascribed to their increased ability in inducing apoptosis and G2/M cell cycle block. SB-T-1213 and SB-T-1250 are also more active than reference compounds in inducing intracellular accumulation of the beta-tubulin subunits. Finally, it is revealed that these novel taxanes have ability to inhibit the function of the P-gp efflux pump on the basis of the Rhodamine 123 assay. These findings strongly suggest that SB-T-1213, SB-T-1250 and SB-T-101187 represent a new tool to overcome innate or acquired P-gp mediated taxane-resistance. © 2000 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM and Bullock G (1994) Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 8: 465–475
Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H and Vielh P (1996) Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77: 292–300
Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T and Traganos F (1997) Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 27: 1–20
De Vincenzo R, Scambia G, Benedetti PP, Fattorossi A, Bonanno G, Ferlini C, Isola G, Pernisco S and Mancuso S (1996) Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. Int J Cancer 68: 340–348
Distefano M, Scambia G, Ferlini C, Gaggini C, De Vincenzo R, Riva A, Bombardelli E, Ojima I, Fattorossi A and Panici PB (1997) Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer 72: 844–850
Ferlini C, Di Cesare S, Rainaldi G, Malorni W, Samoggia P, Biselli R and Fattorossi A (1996) Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry 24: 106–115
Gao Z, Fields JZ and Boman BM (1999) Tumor-specific expression of anti-mdr 1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells. Int J Cancer 82: 346–352
Herrington JD, Di-Nunno L and Rinehart JJ (1998) Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis. Ann Pharmacother 32: 611–612
Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ and Yang CP (1993) Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr Volume, 55–61
Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H and Wilson L (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816–825
Kavallaris M, Kuo DYS, Burkhart CA, Regl DL, Norris MD, Haber M and Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282–1293
Kaye SB (1998) Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 10 Suppl 1: S15–S19
Long BH and Fairchild CR (1994) Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 54: 4355–4361
Manfredi JJ, Parness J and Horwitz SB (1982) Taxol binds tocellular microtubules. J Cell Biol 94: 688–696
Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ and Fruehauf JP (1998) Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389–398
Motulsky HJ and Ransnas LA (1987) Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J 1: 365–374
Naito M and Tsuruo T (1998) Therapeutic approach to drug resistant tumors. Ther Drug Monit 20: 577–580
Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P and Bernacki RJ (1996) Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J Med Chem 39: 3889–3896
Ojima I, Slater JC, Kuduk SD, Takeuchi CS, Gimi RH, Sun CM, Park YH, Pera P, Veith JM and Bernacki RJ (1997a) Syntheses and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III. J Med Chem 40: 267–278
Ojima I, Kuduk SD, Pera P, Veith JM and Bernacki RJ (1997b) Synthesis and structure-activity relationships of nonaromatic taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity. J Med Chem 40: 279–285
Ojima I, Kuduk SD and Chakravarty S (1998) Recent advances in the medicinal chemistry of taxoid anticancer agents. In: Maryanoff BE, Reitz AB (eds). Advances in Medicinal Chemistry, Vol 4. pp 69–124. JAI Press Inc: Greenwich, CT
Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW and Hudes GR (1998) Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77: 562–566
Rao S, Horwitz SB and Ringel I (1992) Direct photoaffinity labeling of tubulin with taxol. J Natl Cancer Inst 84: 785–788
Schiff PB, Fant J and Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665–667
Shapiro AB and Ling V (1997) Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 53: 587–596
Smeets M, Raymakers R, Vierwinden G, Pennings A, van-de-Locht L, Wessels H, Boezeman J and de-Witte T (1997) A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity. Br J Haematol 96: 346–355
Torok M, Gutmann H, Fricker G and Drewe J (1999) Sister of P-glycoprotein expression in different tissues. Biochem Pharmacol 57: 833–835
Uchida N, Combs J, Chen S, Zanjani E, Hoffman R and Tsukamoto A (1996) Primitive human hematopoietic cells displaying differential efflux of the rhodamine 123 dye have distinct biological activities. Blood 88: 1297–1305
Verweij J, Clavel M and Chevalier B (1994) Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5: 495–505
Yu DS, Chang SY and Ma CP (1998) The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br J Urol 82: 544–547
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ferlini, C., Distefano, M., Pignatelli, F. et al. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors. Br J Cancer 83, 1762–1768 (2000). https://doi.org/10.1054/bjoc.2000.1500
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1500
Keywords
This article is cited by
-
Transport, metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ADR-RES cells
Naunyn-Schmiedeberg's Archives of Pharmacology (2012)
-
Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells
Naunyn-Schmiedeberg's Archives of Pharmacology (2005)
-
Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats
British Journal of Pharmacology (2003)